Skip to main content
main-content

Heart failure

News

11-25-2020 | Empagliflozin | News

Empagliflozin LV remodeling not reliant on glucose lowering

The EMPATROPISM trial, which enrolled people without type 2 diabetes, shows reversal of left ventricular remodeling in patients with heart failure and reduced ejection fraction given empagliflozin rather than placebo.

11-19-2020 | Heart failure | News

Targeting fat mass, central adiposity may reduce HF risk in type 2 diabetes

The risk for heart failure falls significantly with reductions in fat mass and waist circumference in overweight or obese people with type 2 diabetes, shows an analysis of data from the Look AHEAD trial.

11-18-2020 | Heart failure | News

Empagliflozin shows heart failure benefits regardless of HbA1c

Empagliflozin reduces the risk for adverse cardiovascular outcomes in people with heart failure and a reduced ejection fraction irrespective of their baseline glycated hemoglobin level, EMPEROR-Reduced trial data show.

11-17-2020 | Empagliflozin | News

Favorable LV remodeling may contribute to empagliflozin benefits

The SGLT2 inhibitor empagliflozin may reverse adverse left ventricular remodeling in people who have heart failure with reduced ejection fraction and type 2 diabetes or prediabetes, shows a randomized trial.

11-17-2020 | Sotagliflozin | News

SOLOIST-WHF: Sotagliflozin beneficial when started shortly after acute heart failure episode

Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.

10-12-2020 | Ertugliflozin | Highlight | News

VERTIS CV secondary analyses indicate ertugliflozin protection against HF

Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.

09-23-2020 | EASD 2020 | Conference coverage | News

Loop diuretics mark poor prognosis even without HF diagnosis

Researchers report that being prescribed a loop diuretic is a marker of poor prognosis among people taking a SGLT2 inhibitor for type 2 diabetes, even if they do not have diagnosed heart failure.

09-15-2020 | SGLT2 inhibitors | News

SGLT2 inhibition ‘could overcome diuretic resistance’

A small randomized crossover trial indicates that treatment with empagliflozin in people with type 2 diabetes and heart failure already using a loop diuretic results in increased urine output without sodium loss.

09-08-2020 | SGLT2 inhibitors | News

Meta-analysis supports mortality reduction with SGLT2 inhibition in HF

A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.

09-01-2020 | Empagliflozin | News

EMPEROR-Reduced boosts case for SGLT2 inhibition in HF irrespective of diabetes

The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.

07-07-2020 | Heart failure | News

Large HbA1c changes, variability linked to HF risk in type 2 diabetes

Large increases or decreases in glycated hemoglobin and a high degree of variability are associated with an increased risk for heart failure among people with type 2 diabetes, shows a secondary analysis of ACCORD trial data.

06-29-2020 | SGLT2 inhibitors | News

CVD-REAL 2 data support cardiovascular benefits of SGLT2 inhibitors

The latest CVD-REAL 2 data confirm clinical trial findings by showing that SGLT2 inhibitors significantly lower cardiovascular disease risk in people with type 2 diabetes, this time in comparison with DPP-4 inhibitors.

06-24-2020 | Heart failure | Highlight | News

Heart failure poses greatest CV mortality risk after type 2 diabetes diagnosis

Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.

06-16-2020 | ADA 2020 | Conference coverage | News

Dapagliflozin may help prevent type 2 diabetes

The SGLT2 inhibitor dapagliflozin reduces the risk for type 2 diabetes by a third in people with heart failure with reduced ejection fraction, particularly those with prediabetes, shows an analysis of data from the DAPA-HF trial.

06-15-2020 | ADA 2020 | Conference coverage | News

Empagliflozin delivers cardiovascular benefits within 3 weeks

A post-hoc analysis of the EMPA-REG OUTCOME trial shows the first benefits of empagliflozin appearing within the third week of taking the sodium-glucose cotransporter 2 inhibitor.

06-14-2020 | ADA 2020 | Conference coverage | News

Canagliflozin reduces risk for first, total HF events in type 2 diabetes with CKD

Treatment with canagliflozin is associated with a reduction in the risk for both first and total heart failure events in people with type 2 diabetes and chronic kidney disease, suggests a post-hoc analysis of the CREDENCE trial.

05-25-2020 | Heart failure | News

Patients stand to gain years from comprehensive HFrEF therapy

Comprehensive therapy with medications including a SGLT2 inhibitor should provide several additional years of event-free and overall survival for people who have heart failure with reduced ejection fraction, shows an analysis in The Lancet.

05-12-2020 | Heart failure | News

Diabetes undertreated among patients with HF and reduced ejection fraction

Diabetes is common among patients who have heart failure with reduced ejection fraction and both conditions together are undertreated despite being associated with a particularly high risk for hospitalization and death, US research suggests.

05-07-2020 | Dapagliflozin | News

FDA okays dapagliflozin for heart failure with reduced ejection fraction

Click through to read more on this approval

05-06-2020 | Heart failure | News

Autoimmune mechanism proposed for some cardiac dysfunction in type 1 diabetes

Researchers show that the presence of multiple cardiac autoantibodies is associated with subclinical myocardial dysfunction in people with type 1 diabetes.

05-01-2020 | Heart failure | News

Blood pressure variability may predict HF risk in people with type 2 diabetes

A post-hoc analysis of the ACCORD and VADT trials suggests that visit-to-visit variability in blood pressure is associated with an elevated risk for heart failure among people with type 2 diabetes.

04-28-2020 | Cardiovascular outcomes | News

Updated analysis shows cardiovascular benefits of type 2 diabetes therapies

Glucose-lowering drugs or strategies reduce the risk for major adverse cardiovascular events and death in people with or at risk for type 2 diabetes, but their impact on heart failure may depend on weight loss, shows an updated systematic review and meta-analysis.

04-06-2020 | Heart failure | Highlight | News

Exercise better than diet to combat early heart changes in type 2 diabetes

The results of a small randomized trial suggest exercise is more helpful than diet for combating early cardiac dysfunction associated with type 2 diabetes, although both may be beneficial.

04-01-2020 | Heart failure | News

Transplant study shows toxic effects of diabetes on the heart

Follow-up of patients after heart transplant reveals rapid cardiomyocyte lipid accumulation, a probable forerunner of diabetic cardiomyopathy, in those with pre-existing type 2 diabetes.

03-31-2020 | SGLT2 inhibitors | Highlight | News

Cardioprotective benefits of dapagliflozin extend beyond people with diabetes

Treatment with dapagliflozin is associated with a significant reduction in the risk for heart failure worsening or cardiovascular death in people with heart failure and reduced ejection fraction regardless of whether or not they have diabetes, shows an exploratory analysis of DAPA-HF trial data.

03-09-2020 | Liraglutide (T2DM) | News

Liraglutide may reduce CV risk regardless of heart failure

A post-hoc analysis of the LEADER trial suggests that liraglutide reduces cardiovascular risk in people with type 2 diabetes regardless of whether they have heart failure.

11-19-2019 | Heart failure | Highlight | News

Dapagliflozin improves life quality for people with heart failure

Dapagliflozin treatment significantly improves self-reported symptoms, physical function, and quality of life in people who have heart failure with reduced ejection fraction, report the DAPA-HF investigators.

11-19-2019 | Heart failure | News

Support for add-on dapagliflozin use in HF patients of all ages

A post-hoc analysis of data from the DAPA-HF trial indicates that the sodium-glucose cotransporter 2 inhibitor dapagliflozin has consistent efficacy and safety profiles among people with heart failure and reduced ejection fraction across a range of age categories.

10-28-2019 | Metformin | News

Long-term metformin use may reduce heart failure risk

Study results suggest that prolonged use of metformin by people with type 2 diabetes may reduce their risk for being hospitalized with heart failure.

09-27-2019 | Heart failure | EASD 2019 | News

DAPA-HF analyses provide further insights into dapagliflozin efficacy

Analyses of metabolic, biomarker, and other outcomes from the DAPA-HF trial presented at the 55th EASD Annual Meeting in Barcelona, Spain, provide additional insights into the efficacy of dapagliflozin in patients with heart failure.

09-25-2019 | Heart failure | EASD 2019 | News

Cardiorenal disease the earliest, most serious CV manifestation in type 2 diabetes

Cardiorenal disease is the foremost cardiovascular complication in people with type 2 diabetes, researchers report at the 55th EASD Annual Meeting in Barcelona, Spain.

09-16-2019 | Heart failure | News

DEFINE-HF: Further support for add-on dapagliflozin as a treatment option for heart failure

Results of the DEFINE-HF trial indicate that add-on dapagliflozin treatment may improve health status among people with established heart failure and reduced ejection fraction.

09-06-2019 | Heart failure | News

Novel risk score stratifies HHF risk in type 2 diabetes

Researchers have developed a novel clinical risk score for hospitalization for heart failure, which identifies people with type 2 diabetes most likely to benefit from sodium-glucose cotransporter 2 inhibition.

09-02-2019 | Heart failure | Highlight | News

Dapagliflozin ‘offers a new approach’ for treating heart failure

The addition of dapagliflozin to standard treatment may be beneficial for patients with established heart failure and reduced ejection fraction, indicate findings from the DAPA-HF trial.

07-18-2019 | Heart failure | Highlight | News

Diabetes-associated heart failure risk greatest in women

Diabetes is a stronger risk factor for heart failure among women compared with men, indicate the results of a large systematic review and meta-analysis.

07-04-2019 | Heart failure | News

Sex difference in HF diabetes impact extended to Asians

Registry data support a larger impact of diabetes on hospitalization and mortality risk in women than men with heart failure.

06-26-2019 | Heart failure | News

Post HF diabetes development increases mortality risk

People who develop diabetes after hospitalization for heart failure have a significantly greater risk for death than people who do not have or develop diabetes, study findings indicate.

06-09-2019 | Type 2 diabetes | ADA 2019 | News

Short-term delays in diabetes onset confer long-term cardioprotective effects

Delaying diabetes onset by at least 6 years in people with impaired glucose tolerance significantly reduces their risk for cardiovascular disease and microvascular complications, show 30-year data from the Da Qing Diabetes Prevention Study.

05-02-2019 | Cardiovascular disorders | News

Metformin may be cardioprotective in patients with coronary artery disease

Findings from the MET-REMODEL trial suggest that metformin treatment may aid regression of left ventricular hypertrophy among nondiabetic patients with coronary artery disease.

04-11-2019 | Empagliflozin | News

EMPRISE shows real-world HF protection with empagliflozin

An interim analysis of EMPRISE shows reductions in heart failure risk with empagliflozin in real-world users that match those reported in the EMPA-REG OUTCOME trial.

03-21-2019 | Heart failure | News

Microvascular disease a marker of heart failure risk in type 2 diabetes

The presence of microvascular disease in people with type 2 diabetes signals a high risk for heart failure, report the EMPA-REG OUTCOME investigators.

03-18-2019 | Dapagliflozin | Highlight | News

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

03-17-2019 | Canagliflozin | News

Canagliflozin may reduce HF events irrespective of ejection fraction

A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.

03-04-2019 | SGLT2 inhibitors | News

Meta-analysis confirms SGLT2 inhibitor heart failure, kidney disease benefits

Sodium-glucose cotransporter-2 inhibitors have a greater effect than glucagon-like peptide-1 receptor agonists on reducing hospitalization for heart failure and kidney disease progression in patients with type 2 diabetes, according to the findings of a systematic review and meta-analysis.

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

09-05-2018 | Heart failure | News

Network meta-analysis backs SGLT2 inhibitors for heart failure prevention

The results of a network meta-analysis offer strong support for use of sodium-glucose cotransporter 2 inhibitors to prevent heart failure (HF) in patients with type 2 diabetes.

07-04-2018 | Heart failure | News

Heart failure particularly high risk in type 1 diabetes patients

The likelihood of dying during or soon after heart failure hospitalization is higher among patients with type 1 than type 2 diabetes, report researchers.

06-08-2018 | Heart failure | News

Established biomarker predicts HF in type 2 diabetes

When levels of N-terminal pro B-type natriuretic peptide are persistently high or rising, patients with type 2 diabetes are at increased risk for being hospitalized with heart failure or dying of cardiovascular causes, research shows.

06-06-2018 | Heart failure | News

Intensive diabetes treatment reduces long-term heart failure risk

Long-term results from the Steno-2 trial show a large reduction in the risk for clinical heart failure among patients with type 2 diabetes who received intensive risk factor control.

03-12-2018 | Canagliflozin | Highlight | News

CANVAS analysis supports SGLT2 inhibitor benefits for HF

The latest analysis of the CANVAS trial indicates that the cardiovascular benefits of canagliflozin in patients with type 2 diabetes may be greatest in those with concomitant heart failure.

03-10-2018 | Heart failure | News

Clinical trial failings leave effect of diabetes medications on HF uncertain

Heart failure is poorly characterized and reported even in cardiovascular outcome trials of glucose-lowering therapies, making it difficult to ascertain the effect of antidiabetic medications on this outcome, say the authors of a systematic review.

11-14-2017 | Canagliflozin | News

Canagliflozin benefits may extend to primary prevention

Further analysis of the CANVAS trial suggests that the benefits of canagliflozin treatment are broadly consistent in type 2 diabetes patients with and without pre-existing cardiovascular disease,

11-13-2017 | Older adults | News

CV complications impact survival in elderly type 2 diabetes patients

Cardiovascular complications, and heart failure in particular, are strongly associated with poor survival in elderly patients with type 2 diabetes, French observational study data show.

10-19-2017 | Vildagliptin | News

Unclear impact of vildagliptin treatment in patients with HF and type 2 diabetes

Results of the VIVIDD trial indicate that it is unclear whether treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin has a beneficial effect on cardiac outcomes among patients with heart failure and type 2 diabetes.

10-18-2017 | Heart failure | News

Glycemic control, drug treatment linked to outcome in patients with HF and type 2 diabetes

Results of a study published in JACC: Heart Failure suggest that glycemic control and drug treatment have complex associations with adverse outcomes among patients with heart failure and type 2 diabetes.

10-11-2017 | Heart failure | News

Sudden death tops CV death causes in type 2 diabetics with atherosclerosis

Sudden death is the most common cause of cardiovascular death among patients with type 2 diabetes and atherosclerotic cardiovascular disease, an analysis of TECOS data shows.

09-22-2017 | Older adults | EASD 2017 | News

Optimizing outcomes: System and patient factors

An EASD session on optimizing patient outcomes included research into the effect of guideline adherence, predictors of changes in medication adherence, and overtreatment of older people with diabetes.

09-14-2017 | SGLT2 inhibitors | EASD 2017 | News

Latest CVD-REAL data bolster cardioprotective effects of SGLT2 inhibition

The CVD-REAL investigators have presented further results demonstrating the effects of sodium-glucose co-transporter 2 inhibitors on cardiovascular outcomes in real-world clinical practice.

09-14-2017 | Heart failure | EASD 2017 | News

Steno-2 shows power of intensive treatment to avert HF

Results from Steno-2 show that intensive multifactorial treatment reduces the risk for heart failure in patients with type 2 diabetes and microalbuminuria.

09-11-2017 | Obesity | News

Metabolically healthy obese concept overturned

A study of 3.5 million people strengthens the evidence against the notion that obesity is only a health risk if people also have metabolic abnormalities.

09-06-2017 | Empagliflozin | News

Empagliflozin improves HF outcomes irrespective of baseline risk

Research shows that treatment with empagliflozin significantly reduces the risk for heart failure hospitalization and cardiovascular disease death among patients with type 2 diabetes, even if their baseline risk is relatively low.

06-14-2017 | Canagliflozin | ADA 2017 | News

Integrated CANVAS: canagliflozin offers cardioprotection at amputation cost

The integrated results of the CANVAS and CANVAS-R studies show that canagliflozin reduces the risk for cardiovascular and renal events in patients with type 2 diabetes at high cardiovascular risk.

03-20-2017 | SGLT2 inhibitors | News

CVD-REAL extends EMPA-REG findings to real-world patients

Findings from the CVD-REAL trial show a protective effect of sodium glucose cotransporter-2 inhibitors against heart failure in real-world patients with type 2 diabetes.

03-18-2017 | Heart failure | News

Neprilysin inhibition could improve glycemic control in diabetic HF patients

A post-hoc analysis of the PARADIGM-HF trial suggests that the inclusion of a neprilysin inhibitor in the medication of patients with heart failure and diabetes might enhance glycemic control.

Image Credits